Interestingly, the loss of function of MerTK increases M1-like anti-tumor phenotypes and reduces M2-type pro-tumor macrophages in the high-MYC prostate cancer mouse model as well as decreases M2-mediated efferocytosis in prostate cancer LNCaP cells [60]. The gene discussed is MERTK; the disease is prostate carcinoma.